Warren Hosseinion - 10 Sep 2026 Form 4 Insider Report for Veraxa Biotech AG

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 10 Sep 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 29 Sep 2026, 16:10:05 UTC
Prior SEC filing: 09 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Warren Hosseinion

Key filing fact

Warren Hosseinion filed Form 4 for Veraxa Biotech AG on 29 Sep 2026.

Key facts

This page summarizes Warren Hosseinion's Form 4 filing for Veraxa Biotech AG.
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 29 Sep 2026, 16:10.

Change

Previous filing in this sequence was filed on 09 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001438327 Primary reporting owner

Hosseinion Warren

Relationship: Director
Address: TALACKER 35, ZURICH,, SWITZERLAND
Signature: /s/ Warren Hosseinion
Signature date: 29 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

No ticker transaction

Ordinary Shares

Purchase

Transaction value
Shares: +6,024
Change %: +0.96%
Price: $1.67^*
Shares after: 634,692
Date: 10 Sep 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The reported securities reflect the forfeiture of 71,332 Ordinary Shares of Veraxa Biotech AG (the "Company"), par value CHF 1/113.25, for no additional consideration, in connection with the Company's business combination consummated on June 10, 2026.